Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 3:43:100924.
doi: 10.1016/j.nmni.2021.100924. eCollection 2021 Sep.

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19

A D Santin  1 , D E Scheim  2 , P A McCullough  3 , M Yagisawa  4 , T J Borody  5
Affiliations
Review

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19

A D Santin et al. New Microbes New Infect. .

Abstract

In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world's most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

Keywords: COVID-19; H. pylori; SARS-CoV-2; ivermectin; spike protein.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A) Excess all-cause deaths (all ages), the national population of Peru. These decreased 14-fold from 1st August through 1st December 2020; then, after IVM use was restricted, increased 13-fold through 1st February. For A and B, y values are 7-day moving averages; for B and C, ages ≥60. Data are from Peru’s National Death Information System (SINADEF). (B) Drops in excess deaths for all states of operation MOT, an army-led program of mass IVM distributions, but Pasco, which had them on three dates. • MOT start date; ▴ peak deaths; ▪ day of peak deaths +30 days. Junin distributed IVM through local channels 13 days before MOT start. (C) Reductions in excess deaths at +30 days after peak deaths for the 25 states by extent of IVM distributions: maximal-MOT (formula image), mean -74%; moderate-local distributions (formula image), mean -53%; and minimal-Lima (formula image), -25%. The absolute value of these reductions by state correlated with extent of IVM distributions with Kendall τb = 0.524, p < 0.002 (Spearman rho = 0.619, p < 0.001). All these data are from publicly accessible Peruvian national databases, with associated frozen datasets available from the Dryad data repository [42].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ergonul O., Yalcin C.E., Erkent M.A., Demirci M., Uysal S.P., Ay N.Z. Who can get the next Nobel Prize in infectious diseases? Int J Infect Dis. 2016;45:88–91. - PubMed
    1. Yagisawa M., Foster P.J., Hanaki H., Omura S. Global trends in clinical studies of ivermectin in COVID-19. Japanes J Antib. 2021;74(1)
    1. Campbell W.C. History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. Curr Pharm Biotechnol. 2012;13(6):853–865. - PubMed
    1. Crump A., Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(2):13–28. - PMC - PubMed
    1. Rajter J.C., Sherman M.S., Fatteh N., Vogel F., Sacks J., Rajter J.-J. Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19 (ICON study) CHEST. 2020 doi: 10.1016/j.chest.2020.10.009. - DOI - PMC - PubMed

LinkOut - more resources